Search
Oritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalOritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). … [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEstradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnEstradiol dienanthate is not currently available in any commercially available products in Canada or the US. … Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone.
Janssen COVID-19 Vaccine
go.drugbank.com/drugs/DB15857ApprovedInvestigationalThe Janssen COVID-19 vaccine is available under an Emergency Use Authorization (EUA) in the US.[L41745] … As of June 2020, a Phase 1/2 clinical trial in adult humans was announced to evaluate the safety, immunogenicity, and efficacy of the ad26.COV.S vaccine in 1045 healthy adults between the ages of 18-55
Corynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalThe vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Boostrix Injektionssuspension in einer FertigspritzeMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Hydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedLacrisertis a formulation of hydroxypropyl cellulose that is used for artificial tears. … , and as a lubricant for artificial eyes.
Categories: Compounds used in a research, industrial, or household settingCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideDiethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalIt is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290) … A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNetarsudil
go.drugbank.com/drugs/DB13931ApprovedInvestigationalhumour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral … the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.